ArticleJournal of clinical microbiology2003
Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 232 citations in OpenAlex.
- Meta-analysis of the Cepheid XpertSexual health · 2019Pooled it
- Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis.PloS one · 2015Pooled it
- Clinical evaluation of the BD ProbeTec™ Chlamydia trachomatis Qx amplified DNA assay on the BD Viper™ system with XTR™ technology.Sexually transmitted diseases · 2011Trial
- Evaluation of the Rapid and Cartridge-Based STANDARD™ M10 STI Panel: Analytical and Clinical Performance for Multiplex STI Detection.Microorganisms · 2026Article
- A single-tube RAA-CRISPR-Cas12a diagnostic platform for rapid detection of Chlamydia trachomatis.Journal of biological engineering · 2025Article
- Evaluation of the APTIMA Combo 2™ kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in frozen semen.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Multicenter Clinical Performance Evaluation of the NeuMoDx CT/NG Assay 2.0.Sexually transmitted diseases · 2025Article
- Bayesian Additive Regression Trees for Group Testing Data.Statistics in medicine · 2025Article
- Article
- Regression analysis of group-tested current status data.Biometrika · 2024Article
- Development of advanced control material for reverse transcription-mediated bacterial nucleic acid amplification tests.Journal of clinical microbiology · 2024Article
- Validation of a New Duplex Real-Time Polymerase Chain Reaction forDiagnostics (Basel, Switzerland) · 2024Article
- Epidemiology ofEpidemiology and infection · 2023Article
- Article
- Impact of risk-based sexually transmitted infection screening in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2022Article
- Article
- Generalized additive regression for group testing data.Biostatistics (Oxford, England) · 2021Article
- Diagnosis of Chlamydia trachomatis genital infections in the era of genomic medicine.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Review
- Using Innovation to Address Adolescent and Young Adult Health Disparities in Pelvic Inflammatory Disease: Design of the Technology Enhanced Community Health Precision Nursing (TECH-PN) Trial.The Journal of infectious diseases · 2021Article
- Comparison between Aptima® assays (Hologic) and the CoBAS® 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The greater sensitivity of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis and Neisseria gonorrhoeae permits the use of urine and other noninvasive specimens, which can increase the reach and decrease the costs of public health screening programs aimed at controlling these infections. This study evaluated the performance of the APTIMA Combo 2 assay, a multiplex assay based on the transcription-mediated amplification reaction, for the simultaneous detection of both pathogens in endocervical swab and urine specimens from females. Combo 2 assay results were compared with patient infected status, which were available by using other commercial NAATs. Sensitivity and specificity for C. trachomatis were 94.2 and 97.6%, respectively, in swabs and 94.7 and 98.9%, respectively, in first-catch urine (FCU). Sensitivity and specificity for N. gonorrhoeae were 99.2 and 98.7%, respectively, in swabs and 91.3 and 99.3%, respectively, in FCU. The assay reliably detected both infections in coinfected patients. The Combo 2 assay can be recommended for use with endocervical swab and urine specimens from females, especially for screening tests for asymptomatic women in sexually transmitted disease surveillance programs. This Food and Drug Administration-cleared assay can be a useful tool in efforts to reduce the prevalence and incidence of C. trachomatis and N. gonorrhoeae infections in sexually active women and to prevent their costly and serious sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.